A High-Profile Decision for the FDA

The U.S. Food and Drug Administration is facing growing pressure from patient advocates, medical experts, and members of Congress to approve an experimental drug from Sarepta Therapeutics for Duchenne muscular dystrophy, a fatal inherited muscle-wasting disease affecting children.

http://ift.tt/1mz0lUY